SLC5A2 and diabetic kidney disease: Thus, the mainstay treatments for DKD now include renin-angiotensin system (RAS) inhibitors, SGLT2 inhibitors, incretin-based agents, and non-steroidal MRAs—collectively referred to as the DKD “fantastic four” [12].